Gstp1a105g Gene Polymorphism In Patients With Advanced Gastric Cancer With Oxaliplatin Chemotherapy Sensitivity Relationship

Objective:The aim of this study was to evaluate the predictive value of the polymorphism GSTP1 Ile105Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Methods:Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. GSTP1 Ile105Val polymorphism was detected by TaqMan-MGB probe allelic discrimination method. Response to treatment was assessed by disease controlled rate. Time to progression, overall survival and toxicities were recorded. Results:The allele frequencies of GSTP1-105 were A/A 52%, A/G 41% and G/G 7%. For patients with A/A and those with A/G+G/G, disease control rate was 48% and 76%(x2=6.947, P=0.014); Median time to progression was 4.0 months and 7.0 months (x2=10.04, P=0.002); Median overall survival time was 7.0 months and 9.5 months (x2=9.22, P=0.002). Conclusion:Patients with at least one 105Val allele have better prognosis and response to oxaliplatin/5-Fu-based regimen as first-line treatment for patients with advanced gastric cancer.